Korean Circ J.  2010 Feb;40(2):55-61. 10.4070/kcj.2010.40.2.55.

Obesity and Preclinical Changes of Cardiac Geometry and Function

• Sung JK
• Kim JY

• KMID: 2297939
• DOI: http://doi.org/10.4070/kcj.2010.40.2.55

Abstract

Overweight and obesity are rapidly increasing in prevalence due to adoption of the westernized life style in Korea. Obesity is strongly associated with the development of cardiovascular risk factors such as diabetes, hypertension, and dyslipidemia. In addition, accumulating evidence suggests that obesity per se has a direct effect on cardiac functional and structural changes that may not be the result of atherosclerosis. In this review, we focus on the view that obesity can influence on the structural and functional changes of the heart, drawing evidence from human and animal studies. We also review influencing factors such as physical, neurohormonal, and metabolic alterations that are associated with changes of the heart in obesity.

Keyword

Obesity; Left ventricular hypertrophy; Left ventricular dysfunction; Diastole

MeSH Terms

Adoption
Animals
Atherosclerosis
Diastole
Dyslipidemias
Heart
Humans
Hypertension
Hypertrophy, Left Ventricular
Korea
Life Style
Obesity
Overweight
Prevalence
Risk Factors
Ventricular Dysfunction, Left

Figure

• 

  Fig. 1 Summary of possible mechanism of structural and functional changes of the heart in obesity. OSA: obstructive sleep apnea, AGE: advanced glycation end-products, IGF-1: insulin-like growth factor-1, TG: triglyceride, RAS: renin angiotensin system.

Reference

1. Park HS, Park CY, Oh SW, Yoo HJ. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev. 2008. 9:104–107.

2. Kim HM, Park J, Kim HS, Kim DH, Park SH. Obesity and cardiovascular risk factor in Korean children and adolescents aged 10-18 years from the Korean National Health and Nutrition Examination Survey, 1998 and 2001. Am J Epidemiol. 2006. 164:787–793.

3. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983. 67:968–977.

4. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002. 347:305–313.

5. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003. 108:754–759.

6. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influence left ventricular energetic in vivo. Am J Physiol Heart Circ Physiol. 2000. 278:H1345–H1351.

7. Ouwens DM, Boer C, Fodor M, et al. Cardiac dysfunction induced by high -fat diet is associated with altered myocardial insulin signaling in rats. Diabetologia. 2005. 48:1229–1237.

8. Avelar E, Cloward TV, Walker JM, et al. Left ventricular hypertrophy in severe obesity: interaction among blood pressure, nocturnal hypoxemia, body mass. Hypertension. 2007. 49:34–39.

9. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of the left ventricular myocardial characteristics associated with obesity. Circulation. 2004. 110:3081–3087.

10. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Di Mario U, Leonetti F. Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obes Res. 2004. 12:1616–1621.

11. Peterson LR, Waggoner AD, Schechtman KB, et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol. 2004. 43:1399–1404.

12. Sundstrom J, Lind L, Valind S, et al. Myocardial insulin-mediated glucose uptake and left ventricular geometry. Blood Press. 2001. 10:27–32.

13. Lauer MS, Anderson KM, Levy D. Separate and joint influence of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1992. 19:130–134.

14. Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race and age to the cardiac structure and functional effect of hypertension. J Am Coll Cardiol. 1994. 24:1492–1498.

15. Fox E, Taylor H, Andrew M, et al. Body mass index and blood pressure influence on left ventricular mass and geometry in African Americans: the Atherosclerotic Risk In Communities (ARIC) Study . Hypertension. 2004. 44:55–60.

16. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 2005. 90:6300–6302.

17. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relation between epicardial adipose tissue and left ventricular mass. Am J Cardiol. 2004. 94:1084–1087.

18. Corradi D, Maestri R, Callegari S, et al. The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts. Cardiovasc Pathol. 2004. 13:313–316.

19. Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, Ambrosi B. Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol. 2007. 121:132–134.

20. Ayer JG, Almafragy HS, Patel AA, Hellyer RL, Celermajer DS. Body mass index is an independent determinant of left atrial size. Heart Lung Circ. 2008. 17:19–24.

21. Di Bello V, Santini F, Di Cori A, et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr. 2006. 19:1063–1071.

22. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol. 2005. 45:87–92.

23. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004. 292:2471–2477.

24. Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the pregression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008. 29:2227–2233.

25. Messerli FH, Ventura HO, Reisin E, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation. 1982. 66:55–60.

26. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol. 1995. 26:195–202.

27. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Grossman E. Myocardial contractility and left ventricular function in obese patients with essential hypertension. Am J Cardiol. 1988. 62:594–597.

28. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003. 52:434–441.

29. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004. 109:2191–2196.

30. Pascual M, Pascual DA, Soria F, et al. Effect of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003. 89:1152–1156.

31. Berkalp B, Cesur V, Corapcioglu D, Erol C, Baskal N. Obesity and left ventricular diastolic dysfunction. Int J Cardiol. 1995. 52:23–26.

32. Morricone L, Malavazos AE, Coman C, Donati C, Hassen T, Caviezel F. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res. 2002. 10:489–498.

33. Chakko S, Mayor M, Allison MD, Kessler KM, Materson BJ, Myerburg RJ. Abnormal left ventricular diastolic filling in eccentric left ventricular hypertrophy of obesity. Am J Cardiol. 1991. 68:95–98.

34. Christoffersen C, Bollano E, Lindegaard ML, et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003. 144:3483–3490.

35. Kozakova M, Muscelli E, Flyvbjerg A, et al. Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab. 2008. 93:2811–2818.

36. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000. 101:899–907.

37. Messerli FH, Christie B, DeCarvalho JGR, et al. Obesity and essential hypertension; hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med. 1981. 141:81–85.

38. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999. 282:1523–1529.

39. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000. 342:1378–1384.

40. Quan SF, Gersh BJ. Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, Blood Institute. Circulation. 2004. 109:951–957.

41. Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest. 2003. 124:594–601.

42. Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005. 146:5341–5349.

43. Mazumder PK, O'Neill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes. 2004. 53:2366–2374.

44. Coort SL, Hasselbaink DM, Koonen DP, et al. Enhanced sarcolemmal FAT/CD 36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes. 2004. 53:1655–1663.

45. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol. 2002. 283:H976–H982.

46. Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007. 56:2457–2466.

47. Unger RH. Lipotoxic disease. Annu Rev Med. 2002. 53:319–336.

48. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000. 97:1784–1789.

49. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes. 2002. 51:1110–1117.

50. Ruano M, Silvestre V, Castro R, et al. Morbid obesity, hypertensive disease and the rennin-angiotensin-aldosterone axis. Obes Surg. 2005. 15:670–676.

51. Hainault I, Nebout G, Turban S, Ardouin B, Ferre P, Quiqnard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab. 2002. 282:E59–E66.

52. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol. 2004. 286:R803–R813.

53. Miner EC, Miller WL. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc. 2006. 81:71–76.

54. Quilliot D, Alla F, Bohme P, et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond). 2005. 29:1321–1328.

55. Carroll JF, Tyagi SC. Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens. 2005. 18:692–698.

56. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995. 269:543–546.

57. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res. 2006. 69:716–725.

58. Park S, Cho YR, Kim HJ, et al. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes. 2005. 54:3530–3540.

59. Purdham D, Zou MX, Rajapurohitam V, Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol. 2004. 287:H2877–H2884.

60. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased TIMP-1 through interleukin-10 expression in human macrophages. Circulation. 2004. 109:2046–2049.

61. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997. 336:1131–1141.

62. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A. 2002. 99:6252–6256.

63. Cigola E, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res. 1997. 231:363–371.

64. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta 1- and beta2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis-toxin sensitive G protein. Circulation. 1999. 100:2210–2212.

65. Relling DP, Esberg LB, Fang CX, et al. High-fat diet-induced juvenile obesity leads to cardiomyocyte dysfunction and upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J Hypertens. 2006. 24:549–561.

66. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995. 76:1194–1197.

67. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004. 350:2549–2557.

68. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004. 27:155–161.

69. Wadden TA, Berkowitz RI, Womble LG, et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005. 353:2111–2120.

70. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev. 2006. 4:CD006162.

71. Padwal RS, Majumdar SR. Drug treatments for obesity: oristat, sibutramine, and rimonabant. Lancet. 2007. 369:71–77.